An Overview of Current Uses and Future Opportunities for Computer-Assisted Design of Vaccines for Neglected Tropical Diseases

References

• Molyneux DH, Savioli L, Engels D. Neglected tropical diseases: progress towards addressing the chronic pandemic. Lancet. 2017;389(10066):312–325. doi:10.1016/S0140-6736(16)30171-4
   PubMed Web of Science ®Google Scholar
• Klohe K, Amuasi J, Kaducu JM, et al. The 2017 Oslo conference report on neglected tropical diseases and emerging/re-emerging infectious diseases - focus on populations underserved. Infect Dis Poverty. 2019;8(1):40. doi:10.1186/s40249-019-0550-8
   Web of Science ®Google Scholar
• WHO. World Health Organization. Available from: https://www.who.int/neglected_diseases/diseases/en/. Accessed October 7, 2020.
   Google Scholar
• Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94. doi:10.1016/S0140-6736(17)31612-4
   PubMed Web of Science ®Google Scholar
• Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737–749. doi:10.1172/JCI84417
   PubMed Web of Science ®Google Scholar
• Rosenberg M, Utzinger J, Addiss DG, Hirayama K. Preventive chemotherapy versus innovative and intensified disease management in neglected tropical diseases: a distinction whose shelf life has expired. PLoS Negl Trop Dis. 2016;10(4):e0004521. doi:10.1371/journal.pntd.0004521
   Web of Science ®Google Scholar
• Akinsolu FT, Nemieboka PO, Njuguna DW, Ahadji MN, Dezso D, Varga O. Emerging resistance of neglected tropical diseases: a scoping review of the literature. Int J Environ Res Public Health. 2019;16(11):1925. doi:10.3390/ijerph16111925
   Web of Science ®Google Scholar
• WHO. Innovative and intensified disease management (IDM). Available from: https://www.who.int/neglected_diseases/disease_management/Innovative_Intensified_Disease_Management/en/. Accessed October 7, 2020.
   Google Scholar
• Nauleau P, Ralph H. Neglected tropical diseases: research bites back. EBioMedicine. 2016;11:1. doi:10.1016/j.ebiom.2016.09.009
   Web of Science ®Google Scholar
• Bragazzi NL, Gianfredi V, Villarini M, et al. Vaccines meet big data: state-of-the-art and future prospects. From the classical 3Is (“Isolate-Inactivate-Inject”) vaccinology 1.0 to vaccinology 3.0, vaccinomics, and beyond: a historical overview. Front Public Health. 2018;6:62. doi:10.3389/fpubh.2018.00062
   PubMed Web of Science ®Google Scholar
• Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity. 2010;33(4):530–541. doi:10.1016/j.immuni.2010.09.017
   PubMed Web of Science ®Google Scholar
• de Sarom A, Kumar Jaiswal A, Tiwari S, et al. Putative vaccine candidates and drug targets identified by reverse vaccinology and subtractive genomics approaches to control Haemophilus ducreyi, the causative agent of chancroid. J R Soc Interface. 2018;15(142):20180032. doi:10.1098/rsif.2018.0032
   Web of Science ®Google Scholar
• Capelli R, Peri C, Villa R, et al. BPSL1626: reverse and structural vaccinology reveal a novel candidate for vaccine design against Burkholderia pseudomallei. Antibodies. 2018;7(3):26. doi:10.3390/antib7030026
   Web of Science ®Google Scholar
• Wang X, Liu Y, Diao Y, et al. Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil. J Transl Med. 2018;16(1):120. doi:10.1186/s12967-018-1501-z
   Web of Science ®Google Scholar
• Malisheni M, Khaiboullina SF, Rizvanov AA, Takah N, Murewanhema G, Bates M. Clinical efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (CYD-TDV) in children: a systematic review with meta-analysis. Front Immunol. 2017;8:863. doi:10.3389/fimmu.2017.00863
   PubMed Web of Science ®Google Scholar
• Fatima K, Syed NI. Dengvaxia controversy: impact on vaccine hesitancy. J Glob Health. 2018;8(2):020312. doi:10.7189/jogh.08.020312
   Web of Science ®Google Scholar
• Zhu S, Guo C. Rabies control and treatment: from prophylaxis to strategies with curative potential. Viruses. 2016;8(11):279. doi:10.3390/v8110279
   PubMed Web of Science ®Google Scholar
• Fisher CR, Schnell MJ. New developments in rabies vaccination. Rev Sci Tech. 2018;37(2):657–672. doi:10.20506/rst.37.2.2831
   Web of Science ®Google Scholar
• WHO. The expanded programme on immunization. Available from: https://www.who.int/immunization/programmes_systems/supply_chain/benefits_of_immunization/en/. Accessed October 10, 2020.
   Google Scholar
• Abela-Ridder B, Martin S, Gongal G, Engels D. Rabies vaccine stockpile: fixing the supply chain. Bull World Health Organ. 2016;94(9):635–635A. doi:10.2471/BLT.16.183012
   Web of Science ®Google Scholar
• Pritam M, Singh G, Swaroop S, Singh AK, Singh SP. Exploitation of reverse vaccinology and immunoinformatics as promising platform for genome-wide screening of new effective vaccine candidates against Plasmodium falciparum. BMC Bioinform. 2019;19(13):468. doi:10.1186/s12859-018-2482-x
   Web of Science ®Google Scholar
• Naz K, Naz A, Ashraf ST, et al. PanRV: pangenome-reverse vaccinology approach for identifications of potential vaccine candidates in microbial pangenome. BMC Bioinform. 2019;20(1):123. doi:10.1186/s12859-019-2713-9
   PubMed Web of Science ®Google Scholar
• Michel-Todó L, Reche PA, Bigey P, Pinazo MJ, Gascón J, Alonso-Padilla J. In silico design of an epitope-based vaccine ensemble for chagas disease. Front Immunol. 2019;10:2698. doi:10.3389/fimmu.2019.02698
   Web of Science ®Google Scholar
• Michel-Todó L, Bigey P, Reche PA, Pinazo MJ, Gascón J, Alonso-Padilla J. Design of an epitope-based vaccine ensemble for animal trypanosomiasis by computational methods. Vaccines. 2020;8(1):130. doi:10.3390/vaccines8010130
   Web of Science ®Google Scholar
• Goodswen SJ, Kennedy PJ, Ellis JT. A gene-based positive selection detection approach to identify vaccine candidates using Toxoplasma gondii as a test case protozoan pathogen. Front Genet. 2018;9:332. doi:10.3389/fgene.2018.00332
   Web of Science ®Google Scholar
• Goodswen SJ, Kennedy PJ, Ellis JT. On the application of reverse vaccinology to parasitic diseases: a perspective on feature selection and ranking of vaccine candidates. Int J Parasitol. 2017;47(12):779–790. doi:10.1016/j.ijpara.2017.08.004
   Web of Science ®Google Scholar
• Pinto PBA, Assis ML, Vallochi AL, et al. T cell responses induced by DNA vaccines based on the DENV2 E and NS1 proteins in mice: importance in protection and immunodominant epitope identification. Front Immunol. 2019;10:1522. doi:10.3389/fimmu.2019.01522
   Web of Science ®Google Scholar
• Huang X, Karabudak A, Comber JD, Philip M, Morcol T, Philip R. A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles. Hum Vaccin Immunother. 2017;13(11):2612–2625. doi:10.1080/21645515.2017.1369639
   PubMed Web of Science ®Google Scholar
• Ramasamy V, Arora U, Shukla R, et al. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice. PLoS Negl Trop Dis. 2018;12(1):e0006191. doi:10.1371/journal.pntd.0006191
   Web of Science ®Google Scholar
• Chen HW, Hu HM, Wu SH, et al. The immunodominance change and protection of CD4+ T-cell responses elicited by an envelope protein domain III-based tetravalent dengue vaccine in mice. PLoS One. 2015;10(12):e0145717. doi:10.1371/journal.pone.0145717
   Web of Science ®Google Scholar
• Dos Santos Alves RP, Pereira LR, Fabris DLN. Production of a recombinant dengue virus 2 NS5 protein and potential use as a vaccine antigen. Clin Vaccine Immunol. 2016;23(6):460–469. doi:10.1128/CVI.00081-16
   Google Scholar
• Quinan BR, Flesch IEA, Pinho TMG, Coelho FM, Tscharke DC, da Fonseca FG. An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8+ T cells and antibody when expressed from modified vaccinia Ankara. Vaccine. 2014;32(25):2972–2979. doi:10.1016/j.vaccine.2014.03.093
   PubMed Web of Science ®Google Scholar
• Chen XY, Li DZ, Zhong XZ, Chen B, Duan ZL, Wen JS. Induction of multiple cytotoxic T lymphocyte responses in mice by a multiepitope DNA vaccine against dengue virus serotype 1. Microbiol Immunol. 2016;60(12):835–845. doi:10.1111/1348-0421.12457
   Web of Science ®Google Scholar
• Roth C, Cantaert T, Colas C, et al. A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice. Front Immunol. 2019;10:1424. doi:10.3389/fimmu.2019.01424
   PubMed Web of Science ®Google Scholar
• Tripathi L, Mani S, Raut R, et al. Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies. Front Microbiol. 2015;6:1005. doi:10.3389/fmicb.2015.01005
   PubMed Web of Science ®Google Scholar
• Nascimento EJM, Mailliard RB, Khan AM, et al. Identification of conserved and HLA promiscuous DENV3 T-cell epitopes. PLoS Negl Trop Dis. 2013;7(10):e2497. doi:10.1371/journal.pntd.0002497
   PubMed Web of Science ®Google Scholar
• da Silva ANMR, Nascimento EJM, Cordeiro MT, et al. Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3). PLoS One. 2009;4(10):e7425. doi:10.1371/annotation/238cbff8-6794-4796-8a8a-a80d3b246757
   Web of Science ®Google Scholar
• Ramanathan B, Poh CL, Kirk K, McBride WJH, Aaskov J, Grollo L. Synthetic B-cell epitopes eliciting cross-neutralizing antibodies: strategies for future dengue vaccine. PLoS One. 2016;11(5):e0155900. doi:10.1371/journal.pone.0155900
   PubMed Web of Science ®Google Scholar
• Khetarpal N, Shukla R, Rajpoot RK, et al. Recombinant dengue virus 4 envelope glycoprotein virus-like particles derived from Pichia pastoris are capable of eliciting homotypic domain III-directed neutralizing antibodies. Am J Trop Med Hyg. 2017;96(1):126–134. doi:10.4269/ajtmh.16-0503
   Web of Science ®Google Scholar
• Serna C, Lara JA, Rodrigues SP, Marques AF, Almeida IC, Maldonado RA. A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease. Vaccine. 2014;32(28):3525–3532. doi:10.1016/j.vaccine.2014.04.026
   PubMed Web of Science ®Google Scholar
• Alvarez MG, Postan M, Weatherly DB, et al. HLA class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop Dis. 2008;2(9):e288. doi:10.1371/journal.pntd.0000288
   PubMed Web of Science ®Google Scholar
• Wang L, Gao J, Lan X, et al. Identification of combined T-cell and B-cell reactive Echinococcus granulosus 95 antigens for the potential development of a multi-epitope vaccine. Ann Transl Med. 2019;7(22):652. doi:10.21037/atm.2019.10.87
   Web of Science ®Google Scholar
• Esmaelizad M, Ahmadian G, Aghaiypour K, Shamsara M, Paykari H, Tebianian M. Induction of protective T-helper 1 immune responses against Echinococcus granulosus in mice by a multi-T-cell epitope antigen based on five proteins. Mem Inst Oswaldo Cruz. 2013;108(4):408–413. doi:10.1590/S0074-0276108042013003
   Web of Science ®Google Scholar
• Pandey RK, Dikhit MR, Kumar A, et al. Evaluating the immunomodulatory responses of LdODC-derived MHC Class-II restricted peptides against VL. Parasite Immunol. 2020;42(4):e12699. doi:10.1111/pim.12699
   PubMed Web of Science ®Google Scholar
• Dikhit MR, Das S, Mahantesh V, et al. The potential HLA Class I-restricted epitopes derived from LeIF and TSA of Leishmania donovani evoke anti-leishmania CD8+ T lymphocyte response. Sci Rep. 2018;8(1):14175. doi:10.1038/s41598-018-32040-x
   Web of Science ®Google Scholar
• Dikhit MR, Kumar A, Das S, et al. Identification of potential MHC Class-II-restricted epitopes derived from Leishmania donovani antigens by reverse vaccinology and evaluation of their CD4+ T-cell responsiveness against visceral leishmaniasis. Front Immunol. 2017;8:1763. doi:10.3389/fimmu.2017.01763
   PubMed Web of Science ®Google Scholar
• De Brito RCF, De Oliveira Cardoso JM, Reis LES, et al. Synthetic peptides elicit strong cellular immunity in visceral leishmaniasis natural reservoir and contribute to long-lasting polyfunctional T-cells in BALB/c mice. Vaccines. 2019;7(4):162. doi:10.3390/vaccines7040162
   Web of Science ®Google Scholar
• Lagatie O, Verheyen A, Van Dorst B, Batsa Debrah L, Debrah A, Stuyver LJ. Linear epitopes in Onchocerca volvulus vaccine candidate proteins and excretory-secretory proteins. Parasite Immunol. 2018;40(11):e12587. doi:10.1111/pim.12587
   Web of Science ®Google Scholar
• Carvalho GBF, De, Pacífico LGG, Pimenta DLF. Evaluation of the use of C-terminal part of the Schistosoma mansoni 200kDa tegumental protein in schistosomiasis diagnosis and vaccine formulation. Exp Parasitol. 2014;139(1):24–32. doi:10.1016/j.exppara.2014.02.003
   Web of Science ®Google Scholar
• de Souza C, Lopes MD, De Oliveira FM, et al. Rational selection of immunodominant and preserved epitope Sm043300e from Schistosoma mansoni and design of a chimeric molecule for biotechnological purposes. Mol Immunol. 2018;93:133–143. doi:10.1016/j.molimm.2017.11.019
   Web of Science ®Google Scholar
• Zhao BP, Chen L, Zhang YL, et al. In silico prediction of binding of promiscuous peptides to multiple MHC class-II molecules identifies the Th1 cell epitopes from secreted and transmembrane proteins of Schistosoma japonicum in BALB/c mice. Microbes Infect. 2011;13(7):709–719. doi:10.1016/j.micinf.2011.03.005
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (NIH). Available from: https://www.nih.gov/. Accessed October 8, 2020.
   Google Scholar
• Vita R, Mahajan S, Overton JA, et al. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 2019;47(D1):D339–D343. doi:10.1093/nar/gky1006
   PubMed Web of Science ®Google Scholar
• Toussaint NC, Maman Y, Kohlbacher O, Louzoun Y. Universal peptide vaccines - optimal peptide vaccine design based on viral sequence conservation. Vaccine. 2011;29(47):8745–8753. doi:10.1016/j.vaccine.2011.07.132
   PubMed Web of Science ®Google Scholar
• Sheikh QM, Gatherer D, Reche PA, Flower DR. Towards the knowledge-based design of universal influenza epitope ensemble vaccines. Bioinformatics. 2016;32(21):3233–3239. doi:10.1093/bioinformatics/btw399
   Web of Science ®Google Scholar
• Shannon CEA. Mathematical theory of communication. Bell Syst Tech J. 1948;27(4):623–656. doi:10.1002/j.1538-7305.1948.tb00917.x
   Google Scholar
• Stewart JJ, Lee CY, Ibrahim S, et al. A shannon entropy analysis of immunoglobulin and T cell receptor. Mol Immunol. 1997;34(15):1067–1082. doi:10.1016/S0161-5890(97)00130-2
   PubMed Web of Science ®Google Scholar
• Quinzo MJ, Lafuente EM, Zuluaga P, Flower DR, Reche PA. Computational assembly of a human cytomegalovirus vaccine upon experimental epitope legacy. BMC Bioinform. 2019;20(S6):476. doi:10.1186/s12859-019-3052-6
   Web of Science ®Google Scholar
• Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and methods for T- and B-cell epitope prediction. J Immunol Res. 2017;2017:2680160. doi:10.1155/2017/2680160
   PubMed Web of Science ®Google Scholar
• Dhanda SK, Mahajan S, Paul S, et al. IEDB-AR: immune epitope database - analysis resource in 2019. Nucleic Acids Res. 2019;47(W1):W502–W506. doi:10.1093/nar/gkz452
   PubMed Web of Science ®Google Scholar
• Doytchinova IA, Guan P, Flower DR. EpiJen: a server for multistep T cell epitope prediction. BMC Bioinform. 2006;7(1):131. doi:10.1186/1471-2105-7-131
   PubMed Web of Science ®Google Scholar
• Nielsen M, Lundegaard C, Lund O, Keşmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 2005;57(1–2):33–41. doi:10.1007/s00251-005-0781-7
   PubMed Web of Science ®Google Scholar
• Besser H, Louzoun Y. Cross-modality deep learning-based prediction of TAP binding and naturally processed peptide. Immunogenetics. 2018;70(7):419–428. doi:10.1007/s00251-018-1054-6
   Web of Science ®Google Scholar
• Hubbard SJ, Thornton JM. NACCESS, computer program. department of biochemistry and molecular biology, university college. London; 1993. Avaliable from: https://www.scirp.org/(S(351jmbntvnsjt1aadkposzje))/reference/ReferencesPapers.aspx?ReferenceID=68275. Accessed October 8, 2020.
   Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–242. doi:10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• PDB-101: learn: guide to understanding PDB data: dealing with coordinates. Available from: https://pdb101.rcsb.org/learn/guide-to-understanding-pdb-data/dealing-with-coordinates. Accessed October 8, 2020.
   Google Scholar
• Terry FE, Moise L, Martin RF, et al. Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases. Expert Rev Vaccines. 2014;14(1):21–35. doi:10.1586/14760584.2015.955478
   Web of Science ®Google Scholar
• Oli AN, Obialor WO, Ifeanyichukwu MO, et al. Immunoinformatics and vaccine development: an overview. ImmunoTargets Ther. 2020;9:13–30. doi:10.2147/ITT.S241064
   PubMed Web of Science ®Google Scholar
• Reche PA. Genome wide prediction of promiscuous epitope for vaccine design. Available from: http://imed.med.ucm.es/PEPVAC/. Accessed December 8, 2020.
   Google Scholar
• Oyarzún P, Ellis JJ, Bodén M, Kobe B. PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity. BMC Bioinform. 2013;14(1):52. doi:10.1186/1471-2105-14-52
   PubMed Web of Science ®Google Scholar
• Schubert B, Kohlbacher O. Designing string-of-beads vaccines with optimal spacers. Genome Med. 2016;8(1):9. doi:10.1186/s13073-016-0263-6
   PubMed Web of Science ®Google Scholar
• De Groot AS, Marcon L, Bishop EA, et al. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine. 2005;23(17–18):2136–2148. doi:10.1016/j.vaccine.2005.01.097
   PubMed Web of Science ®Google Scholar